An ATM genetic test looks for an inherited harmful variant in the ATM gene, which helps cells recognize and repair damaged DNA. People with one pathogenic ATM variant have a moderately increased risk of several cancers, especially female breast cancer and pancreatic cancer, with evidence also supporting increased prostate cancer risk. The size of the risk depends on the exact variant, family history, age, and other factors.
Testing usually uses blood or saliva and is commonly included on a hereditary cancer panel. A positive result can change breast screening, support discussion of pancreatic or prostate surveillance, and guide testing for relatives. It does not mean that cancer is present or certain to develop. Two harmful ATM variants—one inherited from each parent—cause ataxia-telangiectasia, a rare childhood condition that is very different from being a single-variant carrier. Results should be reviewed with a genetics professional because moderate-risk genes require individualized management and some ATM variants, particularly c.7271T>G, may carry risks different from typical truncating variants.
- A pathogenic or likely pathogenic ATM result means cancer risk is increased, not that cancer is inevitable.
- Most female ATM carriers are offered earlier or more intensive breast screening, often including annual MRI and mammography based on age and local guidance.
- Pancreatic and prostate surveillance may be considered, especially when family history or country-specific guidelines support it.
- Each child of a person with one pathogenic ATM variant has a 50% chance of inheriting that variant.
- A variant of uncertain significance should not be used by itself to change screening or recommend preventive surgery.
Table of Contents
- What the ATM Gene Does
- Who May Benefit From Testing
- How ATM Testing Is Performed
- Understanding ATM Results
- Cancer Risks Linked to ATM
- Screening and Risk Reduction
- ATM Results After a Cancer Diagnosis
- Family Planning and Test Limitations
What the ATM Gene Does
ATM stands for ataxia-telangiectasia mutated. The gene provides instructions for a protein kinase that responds to double-strand DNA breaks, one of the most serious forms of DNA damage. ATM activates a network of proteins that pause the cell cycle, repair DNA, or direct a severely damaged cell toward death. This protects the genome from accumulating changes that can lead to cancer.
ATM acts as a tumor-suppressor gene. A person who inherits one nonworking copy still has one working copy in most cells. If a cell later loses or disables the remaining copy, DNA damage may accumulate more easily and contribute to tumor formation. This helps explain why cancer susceptibility is increased but not certain.
Most adults who receive an ATM hereditary cancer result are heterozygous, meaning they carry one pathogenic variant. This is sometimes called a monoallelic ATM variant. It is distinct from biallelic ATM disease. A child who inherits a pathogenic ATM variant from both parents can develop ataxia-telangiectasia, which causes progressive problems with coordination, immune deficiency, characteristic dilated blood vessels, marked sensitivity to ionizing radiation, and increased cancer risk.
Because ataxia-telangiectasia is autosomal recessive, two ATM carriers have a 25% chance in each pregnancy of having an affected child. Most carrier couples do not know they are both carriers until family testing or reproductive screening identifies the possibility. A single ATM carrier does not have ataxia-telangiectasia.
Not all ATM variants carry identical cancer risks. Protein-truncating variants generally reduce or eliminate normal ATM function. Some missense variants alter a single amino acid and require careful classification. The c.7271T>G variant, which causes p.Val2424Gly, has been associated with a higher breast cancer risk than many other ATM variants. Management should therefore consider the exact variant rather than treating every ATM report as interchangeable.
A tumor can also acquire a somatic ATM mutation. Tumor-only testing cannot automatically determine whether an ATM change is inherited. When a potentially pathogenic ATM variant appears on tumor genomic testing, confirmatory germline testing with blood, saliva, or another normal sample may be recommended.
Who May Benefit From Testing
ATM is usually tested as part of a multigene hereditary cancer panel. The test may be offered when personal or family history suggests inherited breast, pancreatic, prostate, ovarian, or other cancer susceptibility. Eligibility rules vary, and many cancer programs now use broader testing criteria than in the past.
Reasons to consider testing include:
- Breast cancer diagnosed at a young age
- Male breast cancer
- Multiple primary breast cancers or cancer in both breasts
- Pancreatic cancer at any age in many current testing programs
- Metastatic or high-risk prostate cancer
- Several relatives with breast, pancreatic, or prostate cancer
- A known ATM pathogenic variant in the family
- An ATM variant found on tumor sequencing
- An ancestry or family pattern that meets local hereditary cancer criteria
Testing an affected relative first usually provides the most informative result. If a person with pancreatic cancer has a pathogenic ATM variant, healthy relatives can then receive a targeted test for that exact change. A negative targeted result in a relative is usually much more reassuring than a negative broad panel when no family cause is known.
A person without cancer may still be tested when the affected relative is unavailable. The genetics team should explain that a negative result may be uninformative if no pathogenic variant has been identified in the family. Cancer risk may remain elevated because of family history even when the panel is negative.
ATM testing is not the same as a diagnostic mammogram, breast biopsy, pancreatic scan, or prostate-specific antigen test. It estimates inherited susceptibility. It cannot show whether a current symptom is cancer. New breast lumps, nipple changes, jaundice, unexplained weight loss, blood in urine, or other concerning symptoms require ordinary clinical evaluation regardless of genetic results.
The test may also reveal reproductive implications. When both partners carry pathogenic ATM variants, a genetics professional can discuss the chance of ataxia-telangiectasia in children. Partner testing is not automatically necessary for every carrier; it is considered based on ancestry, family planning, and personal preferences.
How ATM Testing Is Performed
Germline ATM testing usually uses blood or saliva. No fasting is required. DNA is analyzed from normal cells to determine whether the variant is present throughout the body. Laboratories commonly use next-generation sequencing to read the coding portions and nearby splice regions of ATM, along with deletion and duplication analysis to identify larger missing or extra sections.
A complete report should state:
- The specimen type
- The exact DNA and protein change
- Whether the result is pathogenic, likely pathogenic, uncertain, likely benign, or benign
- Whether deletion and duplication analysis was performed
- Regions that were not well covered
- The transcript used for variant numbering
- Recommendations for genetic counseling or family testing
Many people receive ATM testing through a multigene panel. Panels are efficient because hereditary breast and pancreatic cancer can involve BRCA1, BRCA2, PALB2, CHEK2, CDH1, TP53, mismatch-repair genes, and others. The tradeoff is a higher chance of uncertain findings.
Turnaround commonly ranges from two to six weeks. A targeted family-variant test may be faster. Results should be stored with the full laboratory report, not only a portal summary, because the exact notation and classification are important for future care.
Saliva generally works well, but a repeat blood sample may be requested when DNA quality is poor. In people with a blood cancer, prior stem-cell transplant, or substantial clonal hematopoiesis, blood or saliva may not reliably represent the original germline. Cultured skin fibroblasts or another nonhematologic tissue may then be needed.
Direct-to-consumer genotyping is not a substitute for clinical testing. Consumer arrays examine selected variants and may produce false positives or miss most pathogenic ATM changes. Any medically important result should be confirmed in a certified clinical laboratory before care changes.
Understanding ATM Results
Pathogenic or likely pathogenic
A pathogenic or likely pathogenic ATM variant is considered capable of impairing gene function and increasing cancer susceptibility. “Likely pathogenic” generally carries enough evidence for the same medical management as a pathogenic result.
A positive result does not diagnose cancer and cannot predict the age of onset. It supports a risk-management plan based on the exact variant, sex, organs present, family history, and prior cancers. It also creates an opportunity for cascade testing of relatives.
Negative
A negative result means the laboratory did not find a reportable pathogenic ATM variant. If the test was targeted to a known family variant, the person usually did not inherit that ATM-associated risk. Screening may return to recommendations based on personal and remaining family history.
When no family variant is known, a negative panel does not eliminate hereditary risk. The family may have a pathogenic change in an untested gene, a type of alteration the assay cannot detect, or a risk pattern caused by several genes and shared exposures. High-risk screening can still be appropriate based on calculated risk and family history.
Variant of uncertain significance
A VUS is not a positive result. It means the evidence is insufficient to decide whether the change raises cancer risk. A VUS should not be used by itself to recommend preventive mastectomy, pancreatic surveillance, or testing of healthy relatives. Screening should follow personal and family risk until the variant is reclassified.
Most VUS results are eventually downgraded to benign or likely benign, although timing varies. The testing laboratory should send an amended report to the ordering clinic when classification changes. Patients should keep contact details current and ask how reclassification notifications are handled.
Benign or likely benign
These findings do not explain hereditary cancer risk and usually are not listed prominently. Every person carries many harmless genetic differences. “Mutation” is often used informally, but the medically important question is whether the variant is classified as pathogenic or likely pathogenic.
One variant versus two
A report showing one pathogenic ATM variant indicates carrier status and cancer predisposition. Two pathogenic variants require additional work to determine whether they are on opposite copies of the gene. If they are in trans, ataxia-telangiectasia or a related phenotype may be possible. Adult carriers who are healthy should not assume a second variant is present unless the report specifically documents it.
Cancer Risks Linked to ATM
Risk estimates continue to improve. For many pathogenic ATM variants, female breast cancer risk is often estimated around 20% to 30% over a lifetime, compared with roughly 13% in the general female population. Some studies and variant-specific data produce higher or lower estimates. The c.7271T>G variant may approach high-risk gene levels in some families.
ATM-associated breast cancers are often estrogen receptor positive, but any subtype can occur. The risk of a second cancer in the opposite breast appears lower than with BRCA1 or BRCA2 and may not be substantially increased for many ATM carriers. Decisions about removing the unaffected breast should therefore not be made from ATM status alone.
Pancreatic cancer risk is increased, although absolute estimates vary. Family history can raise concern further. Prostate cancer risk is also increased, and some data suggest a tendency toward more aggressive disease. Evidence for ovarian, colorectal, gastric, and melanoma risk is less consistent or more modest. Screening should not be added for every possible association without guideline support. **Commonly discussed ATM-associated risks**
| Cancer | Strength of association | How the result may affect care |
|---|---|---|
| Female breast | Established moderate increase; variant-specific differences exist | Earlier mammography and breast MRI; individualized prevention discussion |
| Pancreatic | Established increase, with absolute risk influenced by family history | Consider specialized MRI/MRCP or endoscopic ultrasound surveillance |
| Prostate | Established increase in men, with possible aggressive behavior | Earlier or more informed PSA screening discussion |
| Ovarian | Possible small increase; evidence does not support BRCA-level risk | Routine risk-reducing ovary surgery is not based on ATM alone |
| Other cancers | Associations are evolving and often modest | Follow personal and family history rather than unsupported screening |
Absolute risk matters more than a relative-risk headline. Doubling a small baseline risk may still produce a modest lifetime probability. A genetics clinic can combine ATM status with age, breast density, reproductive history, ancestry, prior biopsies, and family history in a validated breast-risk model.
Screening and Risk Reduction
Breast surveillance is the most established management change. Many guidelines recommend annual breast MRI with contrast beginning around age 30 to 35 and annual mammography beginning around age 40, or earlier based on family history. Exact starting ages and whether tests alternate every six months vary by country and patient circumstances.
MRI is more sensitive than mammography in dense breasts but produces more false positives and requires gadolinium contrast. Mammography can detect calcifications that MRI may miss. The tests are complementary. Pregnancy, breastfeeding, kidney function, implants, prior radiation, and access can affect the plan.
Risk-reducing mastectomy is not routinely required for every ATM carrier. It may be discussed when estimated lifetime risk is high, the family history is strong, the variant is associated with higher risk, imaging is difficult, or the person strongly prefers surgery after informed counseling. Surgery greatly reduces breast cancer risk but does not reduce it to zero and has physical and emotional consequences.
Medication such as tamoxifen, raloxifene, anastrozole, or exemestane may lower breast cancer risk in eligible people. Choice depends on menopausal status, clotting history, bone health, uterine status, and side effects. Evidence is not specific to ATM, but many ATM-associated tumors are hormone receptor positive.
Pancreatic surveillance should be performed at an experienced center when recommended. Programs generally use MRI with magnetic resonance cholangiopancreatography, endoscopic ultrasound, or both. Screening often begins around age 50 or ten years younger than the earliest pancreatic cancer in the family, but guidance is evolving. Screening has potential harms, including incidental findings, procedures, anxiety, and surgery for uncertain lesions.
Men can discuss PSA-based prostate screening from around age 40, especially with a family history. The conversation should cover possible benefits and harms, including false positives, biopsy, overdiagnosis, and treatment effects.
Healthy weight, avoiding tobacco, physical activity, limited alcohol, sun protection, and appropriate population screening remain important. These behaviors do not erase inherited risk, but they support overall health and may reduce risks not determined by ATM.
ATM Results After a Cancer Diagnosis
A germline ATM result may influence surveillance for second cancers and testing of relatives. Its role in treatment is more limited and depends on the cancer type.
ATM is involved in DNA-damage response, which has led to interest in platinum chemotherapy, PARP inhibitors, ATR inhibitors, and other targeted approaches. However, ATM is not equivalent to BRCA1 or BRCA2. PARP inhibitor benefit is less consistent in ATM-altered tumors, and approval varies by cancer, drug, and whether the alteration is germline or somatic. Treatment should follow disease-specific evidence rather than assuming that every DNA-repair gene predicts the same response.
For breast cancer, a single ATM pathogenic variant generally does not mean standard radiation therapy must be avoided. Most heterozygous carriers do not show the extreme radiation sensitivity seen in people with ataxia-telangiectasia. Radiation decisions should be based on ordinary oncologic factors, the exact variant, prior exposure, and multidisciplinary review.
Tumor tests may report loss of ATM protein, a somatic variant, or biallelic inactivation. These findings may qualify a patient for a clinical trial even when germline testing is negative. Conversely, a germline variant may be present while the tumor retains the second copy, affecting whether ATM deficiency is biologically complete.
A somatic genetic test and a germline test answer different questions. The tumor test looks for treatment-relevant changes in cancer cells; the germline test assesses inherited risk. Sometimes both are needed.
Family Planning and Test Limitations
First-degree relatives of a carrier each have a 50% chance of carrying the same variant. Adult relatives can choose targeted testing after counseling. Testing children is usually delayed because ATM carrier cancer screening generally begins in adulthood, unless the family situation raises concern for biallelic disease.
Carrier couples can consider prenatal diagnosis or preimplantation genetic testing if avoiding ataxia-telangiectasia is important to them. Other options include donor gametes, adoption, natural conception without testing, or choosing not to have children. Counseling should be nondirective.
Clinical testing detects most coding and copy-number variants but may miss deep intronic changes, complex rearrangements, low-level mosaicism, or variants in poorly covered regions. Classification can differ between laboratories and change as evidence grows. A result should be re-reviewed periodically, especially before a major preventive decision.
Questions for the genetics team include:
- What exact ATM variant was found, and is it associated with higher-than-typical risk?
- What are my estimated breast, pancreatic, and prostate risks based on my family history?
- When should MRI, mammography, pancreatic surveillance, or PSA screening begin?
- Does the result affect treatment for a cancer I already have?
- Should my partner be tested before pregnancy?
- Which relatives should receive targeted testing?
- How will I learn if the variant classification or guidelines change?
Urgent symptoms should be evaluated on their own merits. A genetic result should never delay care for a new breast mass, neurologic symptoms, jaundice, severe abdominal pain, unexplained bleeding, or rapid weight loss.
Keeping the plan current
ATM guidance is changing as larger studies separate risks by variant and cancer type. A plan made several years ago may no longer reflect current starting ages or eligibility for pancreatic surveillance. Carriers should ask for periodic review, particularly after a new cancer occurs in the family, a relative receives a more informative test, or the laboratory reclassifies the variant.
Risk management should also change with age and health. Breast MRI may be less useful when other illnesses limit life expectancy, while a younger carrier with very dense breasts may gain more from combined imaging. Pancreatic surveillance should continue only when a person would be willing and medically able to undergo additional testing or surgery if a suspicious lesion is found. Prostate screening decisions should be revisited as PSA results, urinary symptoms, medications, and overall health evolve.
A written summary can reduce confusion. It should list the exact variant, the cancers considered increased, the next due date for each test, and the relatives who may benefit from targeted testing.
References
- Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) 2025 (Guideline)
- ATM-Related Cancer Predisposition 2026 (Review)
- Breast cancer and ATM mutations: treatment implications 2024 (Review)
- Associations between ATM c.7271T>G and cancer risk: a multicenter study 2025
- Cancer Genetics Overview (PDQ®)–Health Professional Version 2025 (Review)
- ATM (monoallelic pathogenic variants) – risk management 2024 (Guideline)
Disclaimer
This article is educational and does not replace individualized genetic counseling or medical care. ATM cancer risks and screening recommendations depend on the exact variant, sex, age, organs present, family history, prior cancer, and current guidelines. Seek prompt evaluation for new symptoms regardless of genetic-test status.
